The clinical development of second generation of CDK4/6-selective inhibitors, namely Ribociclib (LEE011), Palbociclib and Abemaciclib, has completely changed the prognosis of patients with hormone receptor positive HR+HER2− BC [6, 7]. This evidence concerns the gene CDK4 and breast cancer.